- Home
- RCUS vs PRAX Comparison
RCUS vs PRAX Comparison
Compare RCUS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- PRAX
- Stock Information
- Founded
- RCUS 2015
- PRAX 2015
- Country
- RCUS United States
- PRAX United States
- Employees
- RCUS N/A
- PRAX N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- RCUS Health Care
- PRAX Health Care
- Exchange
- RCUS Nasdaq
- PRAX Nasdaq
- Market Cap
- RCUS 906.4M
- PRAX 950.8M
- IPO Year
- RCUS 2018
- PRAX 2020
- Fundamental
- Price
- RCUS $9.32
- PRAX $56.61
- Analyst Decision
- RCUS Buy
- PRAX Strong Buy
- Analyst Count
- RCUS 8
- PRAX 10
- Target Price
- RCUS $20.86
- PRAX $101.00
- AVG Volume (30 Days)
- RCUS 721.6K
- PRAX 416.3K
- Earning Date
- RCUS 08-07-2025
- PRAX 08-04-2025
- Dividend Yield
- RCUS N/A
- PRAX N/A
- EPS Growth
- RCUS N/A
- PRAX N/A
- EPS
- RCUS N/A
- PRAX N/A
- Revenue
- RCUS $141,000,000.00
- PRAX $8,122,000.00
- Revenue This Year
- RCUS N/A
- PRAX N/A
- Revenue Next Year
- RCUS $28.73
- PRAX $3,567.38
- P/E Ratio
- RCUS N/A
- PRAX N/A
- Revenue Growth
- RCUS N/A
- PRAX 270.02
- 52 Week Low
- RCUS $6.50
- PRAX $26.70
- 52 Week High
- RCUS $18.98
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- RCUS 55.03
- PRAX 68.23
- Support Level
- RCUS $9.14
- PRAX $55.38
- Resistance Level
- RCUS $10.34
- PRAX $61.03
- Average True Range (ATR)
- RCUS 0.48
- PRAX 3.17
- MACD
- RCUS 0.07
- PRAX 0.09
- Stochastic Oscillator
- RCUS 48.91
- PRAX 73.71
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.